Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma.

Saved in:
Bibliographic Details
Title: Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma.
Authors: Mairinger E; Institute of Pathology, University Hospital Essen, Essen, Germany., Wessolly M; Department of Gynecology and Obstetrics, University Hospital Essen, Essen, Germany., Buderath P; Department of Gynecology and Obstetrics, University Hospital Essen, Essen, Germany., Borchert S; Institute of Pathology, University Hospital Essen, Essen, Germany., Henrich L; Institute of Pathology, University Hospital Essen, Essen, Germany., Mach P; Department of Gynecology and Obstetrics, University Hospital Essen, Essen, Germany., Steinborn J; Institute of Pathology, University Hospital Essen, Essen, Germany., Kimming R; Department of Gynecology and Obstetrics, University Hospital Essen, Essen, Germany., Jasani B; Department of Pathology, Targos - A Discovery Life Sciences Company, Kassel, Germany., Schmid KW; Institute of Pathology, University Hospital Essen, Essen, Germany., Bankfalvi A; Institute of Pathology, University Hospital Essen, Essen, Germany., Mairinger FD; Institute of Pathology, University Hospital Essen, Essen, Germany.
Source: Frontiers in oncology [Front Oncol] 2023 Nov 08; Vol. 13, pp. 1252700. Date of Electronic Publication: 2023 Nov 08 (Print Publication: 2023).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2234-943X
DOI:10.3389/fonc.2023.1252700